Ophthalmic Topical Therapeutics Companies

Santen Pharmaceutical Acquired the ophthalmic business of Chemo Unipharm, expanding its portfolio of glaucoma and dry eye treatments.

Sun Pharmaceutical Industries Launched a biosimilar version of Lucentis (ranibizumab) for treating age-related macular degeneration, potentially disrupting the market with a more affordable option.

Novartis Received FDA approval for Vuity (pilocarpine), the first prescription eye drop approved to treat presbyopia, a common age-related vision condition.

Alcon Partnered with Vergence Therapeutics to develop and commercialize gene therapy treatments for eye diseases like Leber's hereditary optic neuropathy.

Akorn Operating Company Launched a generic version of Restasis (cyclosporine), a leading dry eye treatment, offering a more affordable option for patients.

• Santen pharmaceutical co., Ltd. (Japan)


• Sun Pharmaceutical Industries Ltd (India)


• Novartis AG (Switzerland)


• AbbVie (US)


• Bausch & Lomb Incorporated (US)


• Amneal Pharmaceuticals., LLC (US)


• Teva Pharmaceutical Industries Ltd. (Israel)


• Alcon (Switzerland)


• Akorn Operating Company LLC (US)


• Viatris Inc. (US)